Search research articles
Contact Us
Filters
Showing results (11-20 of 84) with videos related to
Page
of 9
Sort By:
Frontiers in Pharmacology
|
June 1, 2016
Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges
Hans-Joerg Fugel, Mark Nuijten, Maarten Postma, et al.
Journal of Cancer Policy
|
July 2, 2022
Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States
Remziye Zaim, Ken Redekop, Carin A Uyl-de Groot
Translational Oncology
|
April 16, 2022
Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
Remziye Zaim, Ken Redekop, Carin A Uyl-de Groot
Journal of Cancer Policy
|
January 2, 2023
Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer
Remziye Zaim, Ken Redekop, Carin A Uyl-de Groot
Diabetes Care
|
March 30, 2004
Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis
Monica Maria Ortegon, William Ken Redekop, Louis Wilhelmus Niessen
BMC Medical Informatics and Decision Making
|
November 30, 2021
How can we discover the most valuable types of big data and artificial intelligence-based solutions? A methodology for the efficient development of the underlying analytics that improve care
Lytske Bakker, Jos Aarts, Carin Uyl-de Groot, et al.
Frontiers in Health Services
|
March 17, 2023
Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment
Remziye Zaim, W Ken Redekop, Carin A Uyl-de Groot
Frontiers in Oncology
|
March 27, 2023
Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
Remziye Zaim, W Ken Redekop, Carin A Uyl-de Groot
Journal of Comparative Effectiveness Research
|
April 29, 2017
The cost-effectiveness of blue-light therapy in the treatment of mild-to-moderate psoriasis
Amir Ansaripour, Hok Bing Thio, Rob Maessen, et al.
Pharmacoeconomics
|
August 11, 2017
Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
Amir Ansaripour, Carin A Uyl-de Groot, W Ken Redekop
Page
of 9
Search research articles
Search
Showing results (11-20 of 84) with videos related to
Sort By:
Page
of 9
Frontiers in Pharmacology
|
June 1, 2016
Economic Evaluation in Stratified Medicine: Methodological Issues and Challenges
Hans-Joerg Fugel, Mark Nuijten, Maarten Postma, et al.
Journal of Cancer Policy
|
July 2, 2022
Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: A comparison of the regulatory approvals in Europe and the United States
Remziye Zaim, Ken Redekop, Carin A Uyl-de Groot
Translational Oncology
|
April 16, 2022
Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
Remziye Zaim, Ken Redekop, Carin A Uyl-de Groot
Journal of Cancer Policy
|
January 2, 2023
Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer
Remziye Zaim, Ken Redekop, Carin A Uyl-de Groot
Diabetes Care
|
March 30, 2004
Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis
Monica Maria Ortegon, William Ken Redekop, Louis Wilhelmus Niessen
BMC Medical Informatics and Decision Making
|
November 30, 2021
How can we discover the most valuable types of big data and artificial intelligence-based solutions? A methodology for the efficient development of the underlying analytics that improve care
Lytske Bakker, Jos Aarts, Carin Uyl-de Groot, et al.
Frontiers in Health Services
|
March 17, 2023
Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment
Remziye Zaim, W Ken Redekop, Carin A Uyl-de Groot
Frontiers in Oncology
|
March 27, 2023
Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
Remziye Zaim, W Ken Redekop, Carin A Uyl-de Groot
Journal of Comparative Effectiveness Research
|
April 29, 2017
The cost-effectiveness of blue-light therapy in the treatment of mild-to-moderate psoriasis
Amir Ansaripour, Hok Bing Thio, Rob Maessen, et al.
Pharmacoeconomics
|
August 11, 2017
Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
Amir Ansaripour, Carin A Uyl-de Groot, W Ken Redekop
Page
of 9